{{Short description|American biotechnology company}} {{Infobox company | name = Beam Therapeutics Inc. | logo = Beam_Therapeutics_logo.svg | logo_size = | type = Public | traded_as = {{ubl|{{NASDAQ|BEAM}}|Russell 2000 component}} | ISIN = US07373V1052 | predecessor = | founders = {{ubl|David R. Liu|J. Keith Joung|Feng Zhang|Nicole Gaudelli|Alexis Komor}} | founded = {{Start date and age|2017}} | location = {{nowrap|Cambridge, Massachusetts, U.S.}} | area_served = | key_people = {{Ubl|John Evans (CEO)|Giuseppe Ciaramella (CSO)}} | industry = Biotechnology | products = | services = | revenue = | operating_income = | net_income = | assets = | equity = | num_employees = 341 (December 31, 2021)<ref>{{cite web |title=Beam Therapeutics Inc. FORM 10-K |url=https://www.sec.gov/ix?doc=/Archives/edgar/data/1745999/000095017022002166/beam-20211231.htm |website=U.S. Securities and Exchange Commission |access-date=14 December 2022}}</ref> | divisions = | website = {{URL|beamtx.com}} }}
'''Beam Therapeutics Inc.''' is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.<ref>{{Cite web|title=Why Beam Therapeutics Climbed 64.5% in June|url=https://www.nasdaq.com/articles/why-beam-therapeutics-climbed-64.5-in-june-2021-07-08|url-status=live|website=NASDAQ|archive-url=https://web.archive.org/web/20210807085831/https://www.nasdaq.com/articles/why-beam-therapeutics-climbed-64.5-in-june-2021-07-08 |archive-date=2021-08-07 }}</ref><ref>{{Cite web|last=Sterling|first=John|date=2021-07-15|title=Base Editing Shows Promise as Common Inherited Lung and Liver Disease Therapy|url=https://www.genengnews.com/news/base-editing-shows-promise-as-common-lung-and-liver-disease-therapy/|access-date=2021-08-07|website=GEN - Genetic Engineering and Biotechnology News|language=en-US}}</ref>
== History == Founded in 2017, the company traces its origins to the Broad Institute of the Massachusetts Institute of Technology and Harvard University. Co-founders include David R. Liu and Feng Zhang.<ref>{{Cite book|last=Isaacson|first=Walter|author-link=Walter Isaacson |title=The Code Breaker|publisher=Simon & Schuster|year=2021|isbn=978-1-9821-1585-2|pages=461–462}}</ref> Prior to its IPO, the company raised nearly $1 billion in venture capital from investors. In a February 2020 IPO, the company raised $180 million.<ref>{{Cite web|last=Dunn|first=Andrew|title=Investors are betting billions that cutting-edge cures can upend how we treat heart disease and transform pharma|url=https://www.businessinsider.com/biotech-gene-editing-crispr-intellia-beam-verve-inside-lab-2021-7|access-date=2021-08-07|website=Business Insider|language=en-US}}</ref>
In January 2022, Pfizer and Beam Therapeutics announced a collaboration to develop therapies for rare diseases using CRISPR.<ref>{{Cite web|title=Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases|url=https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-beam-enter-exclusive-multi-target-research|website=Pfizer}}</ref><ref>{{Cite web|last=Alpert|first=Bill|title=Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases|url=https://www.barrons.com/articles/pfizer-beam-therapeutics-gene-editing-diseases-partnership-51641678989|access-date=2022-02-04|website=www.barrons.com|language=en-US}}</ref>
==See also==
*CRISPR Therapeutics *Editas Medicine *Intellia Therapeutics *Prime Medicine
== References == {{Reflist}}
== External links == * {{official|https://www.beamtx.com}} {{Finance links | name = Beam Therapeutics Inc. | symbol = BEAM | reuters = BEAM.O | bloomberg = BEAM:US | sec_cik = 1745999 | yahoo = BEAM | google = BEAM }}
{{authority control}}
Category:American companies established in 2017 Category:Biotechnology companies of the United States Category:Gene therapy Category:Health care companies based in Massachusetts Category:Pharmaceutical companies of the United States Category:Life sciences industry Category:2020 initial public offerings Category:Companies listed on the Nasdaq